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Abstract
The CD8+ T cell effector mechanisms that mediate control of HIV-1 and SIV infections remain poorly understood. Recent
work suggests that the mechanism may be primarily non-lytic. This is in apparent conflict with the observation that SIV and
HIV-1 variants that escape CD8+ T cell surveillance are frequently selected. Whilst it is clear that a variant that has escaped a
lytic response can have a fitness advantage compared to the wild-type, it is less obvious that this holds in the face of non-
lytic control where both wild-type and variant infected cells would be affected by soluble factors. In particular, the high
motility of T cells in lymphoid tissue would be expected to rapidly destroy local effects making selection of escape variants
by non-lytic responses unlikely. The observation of frequent HIV-1 and SIV escape poses a number of questions. Most
importantly, is the consistent observation of viral escape proof that HIV-1- and SIV-specific CD8+ T cells lyse infected cells or
can this also be the result of non-lytic control? Additionally, the rate at which a variant strain escapes a lytic CD8+ T cell
response is related to the strength of the response. Is the same relationship true for a non-lytic response? Finally, the
potential anti-viral control mediated by non-lytic mechanisms compared to lytic mechanisms is unknown. These questions
cannot be addressed with current experimental techniques nor with the standard mathematical models. Instead we have
developed a 3D cellular automaton model of HIV-1 which captures spatial and temporal dynamics. The model reproduces in
vivo HIV-1 dynamics at the cellular and population level. Using this model we demonstrate that non-lytic effector
mechanisms can select for escape variants but that outgrowth of the variant is slower and less frequent than from a lytic
response so that non-lytic responses can potentially offer more durable control.
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Introduction
There is good evidence that CD8+ T cells control replication of
human (HIV-1) and simian (SIV) immunodeficiency virus [1].
CD8+ T cells can control viral replication via lytic and non-lytic
effector mechanisms. Lytic mechanisms are mediated by secretion
of perforin and granzymes or stimulation of the Fas/FasL pathway
and result in direct killing of the productively-infected cell. Non-lytic
CD8+ T cell effector mechanisms are mediated by multiple soluble
factors that can suppress viral production by infected cells or reduce
the susceptibility of uninfected cells to infection [2–9]. The identity
of these non-lytic factors remains controversial. Some studies [10–
15], but not all [16,17], have reported that the CD8+T cell-secreted
cytokine IFN-c has a suppressive effect on HIV-1 (by upregulating
MHC class I expression and inducing the expression of intrinsic
defence factors including TRIM1a, APOBEC and tetherin).
Similarly, chemokines such as RANTES, MIP-1a and MIP-1b
which bind CCR5 and act as competitive inhibitors of CCR5-
mediated HIV/SIV entry [18] are also thought to play a role,
indeed polymorphisms in the RANTES promoter which increase
mRNA transcription are associated with slower disease progression
[19,20]. However, whether CD8+ T cells secrete these chemokines
in sufficient quantities has been disputed [21,22]. Finally, CD8+ cell
antiviral factor (CAF) is reported to inhibit HIV-1 replication by
blocking transcription [23–25].
Recently, it was reported that, following CD8+ T cell depletion
in SIV-infected macaques, viral load increased significantly,
however the lifespan of SIV-infected cells was unaltered [26,27].
These results led to the suggestion that SIV is controlled
primarily via non-lytic mechanisms; a suggestion which was
further studied and corroborated in [28]. However, the finding
remains controversial [29]. Interestingly, a similar absence of
correlation between the lifespan of productively infected cells and
the strength of the immune response has also been reported in
HIV-1 infection [30].
HIV-1 and SIV are characterised by the selection of viral
mutants that can escape CD8+ T cell responses. The error-
prone virus replication process results in frequent base substi-
tutions (1024–1023 per bp per round of replication [31,32]).
When these mutations lie in or near CD8+ T cell epitopes they
can impair peptide processing, presentation or T cell receptor
binding resulting in reduced T cell recognition of the variant-
infected cells. If the benefit to the virus of evading the CD8+ T
cell response is not outweighed by impaired replication
conferred by the mutation(s) then the variant strain will have a
net growth advantage compared to the wild type strain and will
typically outgrow the wild type. There are numerous studies
reporting the outgrowth of HIV-1 and SIV variants that can
escape CD8+ T cell control during primary [33–36] and chronic
infection [37–40].
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The observation of frequent HIV-1 and SIV escape poses a
number of questions. Most importantly, if CD8+ T cells control
SIV, and potentially HIV-1, primarily by non-lytic mechanisms
then why is viral escape observed? Whilst it is clear that under a
lytic mechanism an escape variant can have a fitness advantage
compared to the wild-type strain, it is less obvious that this holds
in the face of non-lytic control. Although non-lytic factors will be
elicited specifically by wild type-infected cells, these factors will
act non-specifically on both wild type and variant-infected cells.
Consequently, escape variants will not necessarily have a selective
advantage. Indeed, in a well-mixed population, non-lytic CD8+
T cells cannot select for escape variants. The high motility of T
cells in the lymph node and spleen, as measured by intravital two
photon microscopy [41–43], as well as the ability of soluble
factors to diffuse over large distances [44], will tend to destroy
local effects, increasing homogeneity and decreasing the proba-
bility that soluble factors can drive HIV-1 and SIV escape. Is the
consistent observation of viral escape (i.e. selection of escape
variants) proof that SIV and HIV-1-specific CD8+ T cells lyse
infected cells? Additionally, the rate at which the variant strain
replaces the wild type strain is used as a surrogate for the strength
of the CD8+ T cell response assuming that this response is lytic
[45–50]. The relationship between the rate of escape and the
strength of the CD8+ T cell response is unclear when the CD8+
T cell response is primarily non-lytic and may fundamentally
change experiment interpretation. Finally, the potential anti-viral
efficiency of non-lytic mechanisms compared to lytic mechanisms
is unknown.
To investigate the dynamics of non-lytic HIV-1-specific CD8+
T cell responses it is essential to consider in vivo spatial as well as
temporal kinetics. This is not possible with current experimental
techniques nor with the standard ordinary differential equation-
based viral dynamics framework which assumes spatial homoge-
neity. We therefore developed an agent-based in silico approach. A
similar approach has been successfully used to investigate T and B
cell dynamics [51–54]. Using this approach we investigate whether
non-lytic CD8+ T cell responses can select for HIV-1 escape
variants; additionally, we identify factors involved in variant
outgrowth and quantify the relationship between viral control and
the outgrowth rate.
Results
A spatial model of HIV-1 dynamics
We developed a Cellular Automaton (CA; Figure 1a) to simulate
HIV-1 infection in a small volume of the spleen. A CA is a
computer simulation of a system in which cells move in space and
time on a three-dimensional lattice.
We model 6 cell populations: uninfected CD4+ T cells, CD4+ T
cells infected with the wild type strain of HIV-1, CD4+ T cells
infected with an escape variant strain of the virus, CD8+ T cells
which are specific for a single HIV-1 epitope, macrophages, and a
generic splenocyte population. The reticular network of the spleen
is also modelled (see Methods for further details). The model was
parameterised by experimental observations. When parameter
estimates varied in the literature we ran the simulations with a
range of parameter values to check the robustness of our
conclusions.
We explicitly model a single virus-specific CD8+ T cell response
(i.e. clone or clones recognising a single epitope). Initially, we
assume that this CD8+ T cell response controls virus infection by
lysing infected cells (‘‘lytic response’’). This is later generalised to
consider non-lytic effector mechanisms (‘‘non-lytic response’’).
Infected cell death attributable to all other mechanisms (including
other virus-specific CD8+ T cells, activation induced cell death
and virus-induced cytopathicity) is treated as a constant. In
chronic HIV-1 and SIV infection, under the assumption that
CD8+ T cells control virus infection via a lytic mechanism, a single
CD8+ T cell response has been estimated to kill productively
infected cells at a rate of 0.01–0.05 per day [47–49]. We tune the
model to give CD8+ T cell killing rates in this range. If a virus-
specific CD8+ T cell neighbours an infected CD4+ T cell then
three model parameters influence the infected cell death rate: 1)
the probability of recognition (i.e. the probability that the CD8+ T
cell successfully identifies that its neighbour is infected), 2) the
scanning time (i.e. the time to make this decision) and 3) the
duration of the killing process. We found that the CD8+ T cell
killing rate is only weakly dependent on the scanning time and the
duration of killing (Figure S1 in Text S1). We therefore control the
killing rate by adjusting the probability of recognition. Because of
the high motility of T cells the frequency with which CD8+ T cells
neighbour infected cells is high and so only a low probability of
recognition is required to yield a plausible population killing rate (a
probability of recognition of 0.001 to 0.003 gives a mean
population killing rate of 0.01 per day to 0.05 per day). This
probability of recognition seems unexpectedly low. It may be that
the probability of recognition of naturally infected cells, which has
not been estimated experimentally, is genuinely low (perhaps
because of down-regulation of class I molecules from the infected
cell surface or other immune escape mechanism). Indeed, even for
peptide-pulsed splenocytes which would be expected to be easily
recognised, a large proportion of encounters between effectors and
targets do not result in lysis [55]. The only way in which the
probability of recognition of naturally infected cells could be
increased and still give a plausible rate of CD8+ T cell killing, is if
the motility or frequency of specific CD8+ T cells is much lower
than observed. Decreasing the motility or frequency of specific
CD8+ T cells (with a corresponding increase in the probability of
recognition) will not change the frequency of successful contacts
between effectors and targets and so it would not alter the model
conclusions. Conclusions were also robust to an increase in the
Author Summary
The interplay between viruses and the immune system
cannot always be studied with current experimental
techniques or commonly used mathematical models.
Consequently, many important questions remain unan-
swered. The questions we wished to address fall into this
category. Recent evidence strongly suggests that CD8+ T
cells control SIV, and potentially HIV-1, primarily by
secreting anti-viral factors rather than by killing infected
cells. However, this does not seem compatible with the
common observation that HIV and SIV evolve to escape
the immune response. Soluble anti-viral factors, like
RANTES which protects uninfected cells from infection,
would be expected to inhibit both wild-type and variant
virus. Furthermore, the high speed and motility of T cells in
lymphoid tissue will increase homogeneity and again
decrease the likelihood that an escape variant can have a
selective advantage in the face of non-lytic control. We
wanted to understand whether viral escape is proof that
HIV-1- and SIV-specific CD8+ T cells kill infected cells,
determine the factors that facilitate viral escape, and
investigate the comparative efficiency of lytic and non-lytic
responses in controlling viral infections. Here we develop
an elaborate but robust computational framework that
captures T cell kinetics and spatial interactions in lymphoid
tissue to addresses these important questions.
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killing rate via an increase in the probability of recognition.
Finally, the killing rate did not change significantly if the grid size
was increased (data not shown).
The CA model reproduces in vivo dynamics at the cellular
and population level
The speed, motility coefficient and displacement of T cells
has been measured experimentally using two-photon micros-
copy under different experimental settings in multiple studies
[43,56–60]. The average speed of non-activated T cells is
reported to be 10–15 mm/min with a maximum of 25 mm/min
[43,58], the motility coefficient is 50–100 mm2/min and the
displacement is observed to be proportional to the square root
of time (i.e. consistent with a random walk). Most of these
measurements have been made in the lymph nodes; for the
spleen, they are suggested to be comparable but lower [61,62].
In our model simulations, prior to infection, the mean CD4+
and CD8+ T cell speed is approximately 9 mm/min with a
maximum of 25 mm/min (Figure 1b) and the average T cell
motility coefficient is 75 mm2/min. Additionally, the displace-
ment is proportional to the square root of time (Figure S2 in
Text S1). As expected, the mean CD8+ T cell speed is reduced
when infected cells are introduced in the model because of
conjugate formation (Figure S3 in Text S1). The model thus
reproduces the motility of T cells at the cellular level [41–
43,56,61].
The CA model also reproduced cell and virus dynamics at
the population level. Simulated infections displayed a typical
viral expansion phase, with a viraemic peak reached after two
to three weeks (Figure 1c). The infected CD4+ T cells in the
first days post infection (dpi) grow at a rate of 1.5 d21 which is
within the 1–2 d21 range that has been reported [63–65]. Close
to the peak there is a large depletion of CD4+ T cells and the
availability of uninfected target cells becomes limiting. The
CD8+ T cell response which was introduced at day 10 post
infection together with the target cell limitation result in the
slowing down of viral growth and the subsequent decline to a
viral set-point within a few weeks. The proportion of infected
CD4+ T cells at the steady-state (.30 dpi) is of the order of
1023–1022, consistent with experimentally-observed values
[66] .
Non-lytic responses can drive viral escape
We used the CA to simulate lytic and non-lytic CD8+ T cell
effector mechanisms. We divide non-lytic effector mechanisms
(mediated by soluble factors secreted by CD8+ T cells) into those
that protect uninfected cells from becoming infected and those that
reduce viral production by infected cells. CD8+ T cells mediate
non-lytic control via a number of soluble factors. As a case study,
we model RANTES [67]. We assume that RANTES binds to all
uninfected CD4+ T cells that travel through the area of secretion
around the activated HIV-1-specific CD8+ T cells. This effect lasts
for 10 hrs (as measured in [67]) and protects these uninfected
targets from infection. Once this period expires the formerly
protected cells become susceptible to infection. The in vivo area of
diffusivity of RANTES is poorly quantified, we therefore consider
a range of possible values: polarised secretion, and diffusive
secretion with different radii (see Methods). In a similar way, a
non-lytic effect that reduces virion production can be modelled by
abrogating, for a given time, the infectivity of infected cells that
cross the area of secretion. All other parameter values are identical
between all the models; this allows us to study the different control
mechanisms under the same conditions. We introduce an escape
variant-infected population at 50 dpi.
As expected, lytic CD8+ T cells reproducibly drove viral escape
(i.e. selected for the escape variant). The probability of fixation of
the variant strain ranged from 67%–100% as the rate of killing
varied from 0.01 d21 to 0.05 d21. The mean rate of viral escape
(from introduction of the variant) varied from 0.03 d21 to
0.07 d21 over the same range. This agrees well with the
experimentally observed rates in chronic infection which vary
between 0.01 d21 and 0.1 d21 [35,39,49,68].
We found that when CD8+ T cell controlled viral infection via a
non-lytic mechanism, either by reducing infection or by reducing
viral production, then the selection of escape variants was still
repeatedly seen. However fixation was less frequent (Table 1) and
the rate of escape was lower (Figure 2) than in the lytic case (see
next section).
We varied the model parameters to ascertain how robust the
observation of escape from non-lytic factors was. Firstly, we varied
the pattern of soluble factor secretion from polarised (affecting the
9 cells on the nearest grid face) to diffusive with a radius of one,
two, four or five cells (affecting the 26, 124, 728 or 1330 nearest
Figure 1. The cellular automaton model accurately reproduces T cell and viral dynamics at the cellular and population level. (a) A
snapshot of the 3D cellular automaton model. The different coloured nodes represent the different cell populations. (b) The speed of four individual
simulated CD8+ T cells in the CA model as a function of time. The mean speed is 9 mm/min and the mean motility coefficient is 75 mm2/min. (c)
Dynamics of uninfected and infected CD4+ T cells over a course of 150 days. The bars represent the 95% central range values.
doi:10.1371/journal.ppat.1003656.g001
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neighbours respectively). It is unlikely that RANTES (and other
soluble factors that bind to CD4+ T cells) would travel further
than this without being bound given the high density of cells in the
spleen [56,69]. We also varied the probability of CD8+ T cell
recognition, the frequency of specific CD8+ T cells, the half-life of
the soluble factor, the volume of the spleen modelled, the distance
that free virus travels and the initial frequency of escape variant-
infected cells (data not shown). In every case escape from non-lytic
CD8+ T cells remained a frequent occurrence. We therefore
conclude that the observation of viral escape is not incompatible
with a CD8+ T cell response that controls infection entirely via a
non-lytic mechanism.
The non-lytic CD8+ T cell effector mechanisms affect both wild
type and escape variant populations; so under the assumption of
spatially well-mixed cell populations, the escape variant would not
be expected to have an advantage. We explored whether there are
spatial patterns that can explain the observed advantage of the
variant population under a non-lytic control mechanism. Although
the median frequency of infected cells neighbouring a wild type-
and variant-infected cell was similar, the overall distribution is
highly skewed. A wild type-infected cell has a significantly higher
frequency of wild type-infected than variant-infected cells in its
immediate neighbourhood (p,0.001, two-tailed,Wilcoxon rank
sum test) and likewise for a variant-infected cell (Figure 3). To
investigate the evolution of this spatial heterogeneity over time we
tracked the neighbourhoods of CD8+ T cells following triggering
by wild type-infected cells. The proportion of infected cells in the
neighbourhood that were infected with wild type and variant virus
was recorded for the duration of secretion of the non-lytic factors.
This analysis (Figure 4) showed that the majority of cells that
Figure 2. Non-lytic CD8+ T cells reproducibly drive viral escape but escape is slower than that driven by lytic CD8+ T cells. This was
observed both for non-lytic factors that reduce infection and non-lytic factors that reduce production; for the three different probabilities of target
cell recognition considered and for all secretion patterns considered. Abbreviations: NLi: Non-lytic model - reducing infection of uninfected CD4+ T
cells, NLp: Non-lytic model - reducing virion production, TO: target cell only affected, P1: Polarised secretion (r = 1), D1: Diffusive secretion (r = 1) and
D2: Diffusive secretion (r = 2). Different colours represent different effector mechanisms (black: lytic, pink: NLi, green: NLp) and different symbols
represent different patterns of secretion (open circle: P1, open triangle: D1, x: D2, cross:TO). The horizontal bars represent the mean. Lytic CD8+ T cells
drive escape significantly faster and more frequently than CD8+ T cells operating via a non-lytic mechanism which impairs viral infection or a non-lytic
mechanism that impairs virion production. Mean rates of escape from lytic CD8+ T cells: 0.033 d21, 0.048 d21, 0.069 d21 for Pr = 0.001, Pr = 0.002,
Pr = 0.003 respectively. Mean rates of escape from non-lytic CD8+ T cells that impair infection: 0.013 d21, 0.010 d21, 0.011 d21 for Pr = 0.001,
Pr = 0.002, Pr = 0.003 respectively. Mean rates of escape from non-lytic CD8+ T cells that impair virion production: 0.016 d21, 0.015 d21, 0.018 d21 for
Pr = 0.001, Pr = 0.002, Pr = 0.003 respectively. In every case the difference between lytic and non-lytic escape rates is significant (P,0.001, Wilcoxon
Mann Whitney test two-tailed). The frequency of fixation is given in Table 1.
doi:10.1371/journal.ppat.1003656.g002
Table 1. The percentage of simulations that result in variant fixation.
Pr Models
Lytic Non lytic (impair infection) Non lytic (impair production)
- P1 D1 D2 TO P1 D1 D2
0.001 67% 43% 67% 24% 50% 57% 65% 43%
0.002 76% 29% 43% 38% 64% 57% 79% 64%
0.003 100% 48% 48% 38% 64% 64% 42% 64%
Abbreviations: Pr = Probability of recognition by CD8+ T cells, TO = Target Only, P1 = Polarised secretion (r = 1), D1 =Diffusive secretion (r = 1) and D2=Diffusive
secretion (r = 2).
doi:10.1371/journal.ppat.1003656.t001
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would be affected by the secreted factors were indeed wild type
infected, confirming our finding that the heterogeneity offers the
variant a selective advantage. However, variant-infected cells were
also present in the neighbourhood and their frequency increased
significantly over time (p,1026, two-tailed, Spearman correlation
coefficient = 0.93).
It has been observed that the rate of escape is significantly more
rapid in acute than in chronic infection [45,47,49]. During acute
infection the rate of escape is up to 0.4 per day with a median of
0.25 per day [47]. We investigated whether, during the acute
phase, lytic and non-lytic responses could drive escape at such
rapid rates. We found that seeding the variant during the acute
phase (15 dpi) doubled the rate of escape from lytic responses but
had little impact on the rate of escape from non-lytic responses.
Consequently, escape from lytic responses was in the observed
ranges but escape from non-lytic responses was not. Even in the
extreme case, chosen to favour rapid escape, of a high probability
of recognition (Pr = 0.003) and a polarised secretion pattern the
maximum rate of escape from a non-lytic response was only 0.05
per day. This indicates that, at least during acute infection, HIV-1-
specific CD8+ T cells that operate via a lytic mechanism are likely
to be present (it does not rule out the possibility that non-lytic
CD8+ T cells are also present at this time).
Viral variants that evade non-lytic CD8+ T cell responses
have a slow rate of escape
We find that viral escape from a non-lytic response is slower
than escape from a lytic response (Figure 2). We investigated
whether this slower escape can be attributed to weaker anti-viral
control by a non-lytic response. For the lytic response, as the
probability of recognition was increased the anti-viral control
exerted by lytic CD8+ T cells increased; i.e. the number of new
infections prevented increased and the frequency of infected cells
at set point decreased (Figure 5A, Figure S4 in Text S1). As
expected both the rate of escape and the probability of variant
fixation increased proportionally (Figure 2, Table 1 & data not
shown). Under the same conditions, for the non-lytic response that
decreased infectivity, we found that as the probability of
recognition or area of secretion was increased there was a
substantial increase in the number of uninfected cells that were
protected (Figure 5B) but that, in marked contrast, the anti-viral
control was unchanged; i.e both the number of new infections
prevented (Figure S5 in Text S1) and the frequency of infected
cells at setpoint remained approximately constant (Figure 5A). For
the minimum probability of CD8+ T cell recognition considered
(Pr = 0.001), anti-viral control (both the number of infections
prevented and the frequency of infected cells at setpoint) was
similar between the lytic and non-lytic model of the CD8+ T cell
response (Figure 5A) and so at this point a fair comparison of the
escape rates could be made. Despite the similar anti-viral control,
lytic CD8+ T cells still drive escape significantly faster (approx.
0.033 per day vs 0.013 per day, p,0.001; Figure 2) and more
frequently (67% v 43%, p,0.05; Table 1) than CD8+ T cells
operating via a non-lytic mechanism which impairs viral infection.
Repeating the simulations for a non-lytic mechanism that reduces
virion production yielded similar results (Figures S6, S7, S8 in
Text S1). The rate of viral escape, in the case where variant fitness
costs are low, is used to compare the magnitude of anti-viral
control [45–50]. Our results suggest that this approach is valid for
comparisons between lytic responses but cannot be used to
compare lytic with non-lytic responses as the same degree of anti-
viral control results in significantly different escape rates.
Antiviral control mediated by non-lytic effector
mechanisms is difficult to enhance
HIV-1 escape from CD8+ T cells has been implicated in disease
progression and in the failure of T cell-based vaccines in animal
models [40,70–72]. The observation that, despite comparable
anti-viral control (as measured by the number of new infections
prevented or by the frequency of infected cells at setpoint),
Figure 3. Existence of clusters of wild type and variant-infected
cells. The percentage of wild type-infected cells neighbouring a wild
type-infected cell is significantly higher than the percentage of variant-
infected cells. The same is true for variant-infected cells. We track
simulated wild type and variant-infected CD4+ T cells (<500 cells) for
multiple timepoints. Abbreviations: WT/WT=Wild type infected cells in
the immediate area (r = 1, i.e. 26 nodes considered) surrounding a wild
type-infected cell, WT/VAR=Wild type infected cells in the immediate
area surrounding a variant-infected cell, WT/ALL=Wild type-infected
cells on the whole grid. VAR/VAR, VAR/WT and VAR/ALL are defined
similarly.
doi:10.1371/journal.ppat.1003656.g003
Figure 4. Infected cells in the neighbourhood of CD8+ T cells
secreting non-lytic factors. The mean fraction of wild type-infected
cells neighbouring secreting CD8+ T cells was evaluated over time. We
tracked the proportion of wild type- and variant-infected cells in the
immediate neighbourhood (radius = 1, i.e. 26 neighbours) of 5,425 se-
creting CD8+ T cells. In these runs, CD8+ T cells secreted non-lytic
factors for 30 mins after triggering and were tracked for 34 minutes.
The proportion of wild type-infected cells was high (i.e. the majority of
affected cells were wild-type infected, conferring an advantage upon
variant-infected cells), but not 100% (i.e. some variant-infected were
also affected by the factor) and the proportion of wild type-infected
cells decreased significantly over time (i.e. the spatial heterogeneity that
conferred an advantage upon escape variants was short lived). The
correlation between the proportion of wild type-infected cells and time
during the 30 mins post CD8+ T cell-triggering was significant,
Spearman correlation coefficient =20.93, p,1026.
doi:10.1371/journal.ppat.1003656.g004
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non-lytic CD8+ T cell responses drive viral escape less frequently
and less rapidly than lytic CD8+ T cell responses makes them an
attractive target for boosting to enhance durable anti-viral control.
We therefore examined what qualities of a non-lytic response were
associated with anti-viral control.
There are four main quantities that could potentially strengthen
the non-lytic response: 1) the radius of secretion, 2) the probability
of recognition, 3) the duration of the effect of the soluble factor and
4) the size of the CD8+ T cell population. We already found that
increasing the first two parameters did not substantially increase
the anti-viral control (Figure 5B). Additionally, when we double
the duration of the effect of the soluble factor from 10 to 20 hrs,
we find no consistent substantial impact on anti-viral control either
for CD8+ T cell secreted factors that block infection (Figure 5C) or
block viral production (data not shown). Finally, we increase the
size of the effector population (specific for a single epitope) from
0.5% to 1.5% of the splenocytes. Although, the number of cells
that are protected by the soluble factors increases (Figure S9 in
Text S1), again we find no significant increase in the anti-viral
effect either in terms of new infections prevented (data not shown)
or on the set-point of the infected cell population (Figure 5D). This
result is in stark contrast to lytic control where the same increase in
the probability of recognition or in the size of the effector
population results in substantially better anti-viral control
(Figure 5D, Figure S4 in Text S1). To investigate whether the
anti-viral control conferred by non-lytic CD8+ T cells is bounded
(i.e. cannot be increased above the observed value) we increased
the model parameters substantially (beyond the physiological
range). Under these circumstances, in some cases, we did observe
significant improvement in anti-viral control. It was apparent that
non-lytic responses that reduce infectivity were particularly hard to
boost (Figure S10 and S11 in Text S1). Our findings taken
together suggest that, whilst not impossible, it is difficult to
enhance the anti-viral control conferred by non-lytic CD8+ T cell
responses.
Discussion
CD8+ T cells can control HIV viral burden through multiple
mechanisms [9,18,26,27,73] which can be broadly classified as
lytic and non-lytic. Although the existence of non-lytic CD8+ T
cell-secreted factors in HIV-1 infection is shown by multiple
studies (reviewed in [5]), little is known about the dynamics or in
vivo relevance of such a response. Quantifying the CD8+ T cell
non-lytic immune control requires information about spatial and
temporal aspects of the system that cannot be captured with
Figure 5. The immune control exerted by lytic and non-lytic CD8+ T cell responses. (A) The frequency of productively infected cells at
setpoint for varying probability of CD8+ T cell recognition and for different secretion patterns. As the probability of recognition increases, the
frequency of infected cells decreases for the lytic response but remains approximately constant for the non-lytic response for all secretion patterns.
When Pr = 0.001 (first box) the frequency of infected cells is similar for the lytic and non-lytic responses (B) Number of uninfected CD4+ T cells
protected from infection by a non-lytic CD8+ T cell response. The number of cells protected increases significantly as the probability of recognition
and the area of diffusion increases (cumulative number by 50 dpi). (C) Set-point of productively infected cells when varying the duration of the
protective effect of the soluble factor. Number of infected cells at setpoint does not decrease when the duration of effect is increased even though
the number of cells protected robustly increases (D) Set-point of productively infected cells for different sizes of the epitope-specific CD8+ T cell
clones. Here we show the results for the non-lytic control that blocks viral infection, similar results were found for non-lytic control that blocks viral
production (Figures S6, S7 in Text S1 and data not shown). Results for more extensive parameter combinations are shown in supplementary
information (Figures S10 and S11 in Text S1). The percentage of productively infected cells is calculated from 40–50 dpi. Abbreviations: NLi: Non-lytic
model - blocking infection of uninfected CD4+ T cells, P1 = Polarised secretion (r = 1), D1 =Diffusive secretion (r = 1) and D2=Diffusive secretion (r = 2).
doi:10.1371/journal.ppat.1003656.g005
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current in vivo experimental techniques. Instead we address these
questions in silico by constructing a 3D cellular automaton model of
HIV-1 dynamics parameterised by experimental data. Our aim is
two-fold: 1) to investigate whether non-lytic CD8+ T cells can
drive viral escape and 2) to explore the properties of non-lytic
control.
We found that, for a wide range of model assumptions, both a
non-lytic control mechanism that blocks viral infection (e.g
RANTES) or restricts viral production (e.g. IFN-c) reproducibly
drives viral escape (Figure 2). Given that soluble factors diffuse and
T cell motility is rapid this result is highly non-intuitive. We found
localised clusters of wild type and variant-infected cells (Figure 3)
that could enable viral escape since anti-viral factors elicited by
wild type-infected cells would be more likely to affect their
neighbours (other wild type-infected cells) and thus the variant-
infected cells would have an advantage even though they are
equally susceptible to non-lytic factors. Tracking this process over
time (Figure 4) confirmed that the majority of infected cells in the
vicinity of a secreting CD8+ T cells are indeed infected with wild
type virus but that this proportion decreases significantly over
time. We conclude that the variant has an advantage but this
advantage is limited because the fast timescale of T cell motility
destroys spatial heterogeneity. However, this is a dynamic process
and the repetitive formation of such heterogeneous clusters is likely
to provide a net advantage to the variant-infected cell population
that can support its outgrowth.
We find that, when the lytic and non-lytic immune pressures are
comparable in terms of number of new infections prevented and
set-point proviral load, non-lytic responses drive escape signifi-
cantly more slowly and less frequently than lytic responses
(Figure 2). Consequently, the rate of escape cannot be used as a
surrogate for the degree of antiviral control when comparing lytic
and non-lytic effector mechanisms as the same control mediated
via different effector mechanisms results in different rates of
escape. At first sight, the observation that non-lytic CD8+ T cells
drive escape slowly is reminiscent of a finding in [47] based on a
theoretical model that assumes spatial homogeneity and thus has
to impose escape externally. However, the two results are distinct,
in the latter case the decreased rate of escape is attributable to
strong CD8+ T cell control relative to the rate of viral replication
rather than spatial factors.
It has been observed that the rate of escape during chronic
HIV-1 infection is significantly slower than during acute infection
[45,47,49]. We found that, when modelling chronic infection, the
predicted rate of escape of variants escaping both lytic and non-
lytic responses was broadly comparable with that observed
experimentally. However, when simulating viral escape dynamics
during the acute phase we found that it was impossible for a non-
lytic (but not a lytic) response to drive escape at a rate comparable
with experimental observation. This indicates that at least during
acute infection, HIV-1-specific CD8+ T cells may operate
predominantly via a lytic mechanism. It would be interesting to
test this hypothesis by repeating the CD8+ T cell depletion
experiment [26,27] during acute infection. The reason behind the
slower rate of escape in chronic infection is unknown. One possible
mechanism, highlighted by this study, is a shift from a response
dominated by lytic CD8+ T cells to one dominated by non-lytic
CD8+ T cells.
Our findings have implications for studies of HIV progression
and vaccine development. The appearance of escape mutants has
been associated with loss of viral control and disease progression
[70]; though there are numerous cases where escape does not
result in progression or where progression occurs in the absence of
escape [74,75]. Our results indicate that, even for matched levels
of antiviral control, non-lytic responses drive escape more slowly
and less frequently than lytic responses (Figure 2), offering the
potential of durable anti-viral control with less risk of viral escape.
Furthermore, a non cytolytic effector mechanism has other
advantages: it can act on multiple targets simultaneously, it can
suppress infection without eliminating potentially vital cell
populations and it can exhibit a ‘bystander’ protective effect [5].
Therefore, it can be argued that the tipping of balance towards
non-lytic responses can be a strong weapon in the fight of HIV
infection.
However, we find that it is difficult to enhance the efficiency of a
non-lytic response. An increase in the probability of target cell
recognition, the frequency of CD8+ T cells, the duration of the
effect of soluble factors or the area of diffusion (within the
physiological range) all failed to lead to better anti-viral control
(Figure 5). In contrast a lytic CD8+ T cell response was easily
‘‘boosted’’. This implies that even if many uninfected cells are
protected from infection or the infectivity of many infected cells is
reduced, if the infected cells are not eliminated, there are still
enough available targets to sustain the set-point viral burden.
Importantly, the difficult of boosting non-lytic responses is a
function of the ratio of infected to uninfected targets. During in
vitro suppression assays, where the majority of potential targets are
infected, it is therefore likely to be easier to enhance non-lytic
responses. However in vivo, where infected cells are a small
minority, potentially very high numbers of effector CD8+ T cells
are needed for efficient non-lytic suppression since even in theory
it proved difficult to enhance a non-lytic response under conditions
that readily enhanced lytic control.
In summary, this model provides a new framework for
investigating CD8+ T cell control in HIV-1 infection. We find
that, for comparable levels of anti-viral control, non-lytic responses
select for escape variants less frequently and more slowly than lytic
responses. However, anti-viral control mediated by a non-lytic
response was difficult to enhance. Most importantly we repeatedly
and reproducibly found that over a wide range of parameters,
non-lytic CD8+ T cells were able to select for escape variants
despite rapid T cell motility and soluble factor diffusion. We
conclude that the observation of viral escape does not constitute
proof that CD8+ T cells kill virus-infected cells in SIV and HIV-1
infection.
Methods
The CA lattice consists of nodes and edges and is updated at
every timestep (30 sec). Each node of the lattice represents a cell or
part of the cell and has 26 neighbours. The grid size is set to
125,000 cells in most simulations (roughly 0.005–0.5% of the
splenic volume); however, we do vary the grid size in order to
explore if it affects our conclusions. The CA lattice is governed by
toroidal boundary conditions where a cell leaving one side of the
lattice reappears on the opposite side.
Cell sizes
Most cells are represented by one node on the lattice, the
exception is macrophages which occupy four nodes; this is to
reflect the difference between the diameter of T cell which is 7 mm
and that of macrophages which is calculated to be 10–16 mm and
has been implemented as such in [53]. An additional set of nodes
represents the reticular network, a rigid cellular structure found in
the spleen. These nodes are immobile and act as spatial obstacles
to the overall movement of cells. Only a small percentage (approx.
1%) of nodes is considered to be unoccupied since the spleen is a
dense organ. The nodes that are left after setting all frequencies of
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the specific cell populations within biological ranges (Supplemen-
tary Methods in Text S1) are considered to be unspecified
splenocytes. The cellular automaton is implemented in C++.
Model assumptions
Modelling the dynamics of HIV-1 infection demands the
incorporation of many complex rules. However, focusing on the
specific questions that we are aiming to address and in order to
speed-up the simulations and ease the interpretation of our results,
we allowed for multiple assumptions to be included in the model as
long as these would not alter the outcome of the tested hypotheses.
The following assumptions were made:
1. The same motility parameters apply for all cell types since we
focus on T cells for which the parameters have been
experimentally defined in multiple studies [43,56–60] .
2. We keep the density of the reticular network constant since it
has been shown that it does not substantially effect cell-cell
interactions [76].
3. Free virus is not explicitly included in the model. Infection (via
free virions or cell-cell transmission) is simulated via a
probability of infection of uninfected cells neighbouring a
productively infected cell. This probability is set based on
estimates of the HIV viral reproduction rate [65].
4. We do not make any distinction between activated and non-
activated CD4+ T cells.
5. We explicitly model a CD8+ T cell response specific for a single
HIV-1 epitope. Because we focus on the dynamics of infection
after set point viral load we do not consider proliferation or
contraction of this CD8+ T population.
6. There is no fitness cost associated with the escape mutations.
Fitness costs will act to slow the rate and frequency of escape.
There is evidence suggesting that, in many cases, this fitness
cost can be low [49,77].
7. We do not consider superinfection of infected cells. Findings
regarding superinfection remain controversial in the literature
[78,79].
CD4+ T cell proliferation
We define the influx of CD4+ T cells using in vivo proliferation
rate estimates obtained with deuterated glucose in 7 treatment-
naive HIV+ subjects [80] . The authors estimate that the mean
CD4+ proliferation rate in HIV+ subjects is 0.025 d21 when their
mean CD4+ T cell count is approximately 400 ml21, i.e. about
33% of a normal count. As an estimate of the proliferation rate we
use a Hill function where j is calculated such that the probability of
entering the grid, pinflux when the CD4+ T cell count is decreased
by 67% provides a CD4+ T cell proliferation rate of 0.025 d21
and n is chosen to provide a plausible change of pinflux with respect
to the percentage of CD4+ T cells, U, at any given timepoint. We
note that pinflux?0 when CD4+ T cell count goes to normal, i.e.
100% of the initial population. This formulation simulates a
homeostatic influx mechanism for the replenishment of CD4+ T




The probabilities which define whether a CD4+ T cell that
entered the grid will be uninfected or infected (with the wild type
or the variant strain) depend on the relative sizes and lifespans of
these populations (see Supplementary Methods in Text S1). The
new CD4+ T cells introduced in the grid appear at random free
space cells as in [81].
Virus reproduction and death
Reproductive rate. In the context of within host viral
infection, the basic reproductive ratio, R0, is defined as the
number of secondary infected cells produced by a primary infected
cell during its lifetime assuming that uninfected target cells are not
limiting. We consider R0 = 6 in accordance with estimates reported
in the literature [65,82]. At this viral reproduction rate, we record
a peak in infected cell population 15–20 days post infection (dpi).
HIV-1 infection of new cells is thought to occur over a relatively
short radius [83–85]; this is probably attributable to a number of
factors including high uninfected cell density in the lymphoid
tissues (meaning viral particles will immediately attach to nearby
cells), inherent instability of HIV-1 virions [86,87] rapid clearance
of virions in vivo [88,89] as well as direct cell-to-cell transmission
[90–94]. Accordingly, we model the spread of infection (mediated
by free virions and cell-cell transmission) by allowing all cells
neighbouring a productively infected cell (26 in total, r = 1) to have
a probability of becoming infected every timestep (30 seconds). We
also investigated the impact of increasing the distance that free
virions can travel by allowing the 124 cells (r = 2) nearest a
productively infected cell to have a probability of infection at every
timestep.
Death rate. Since we are interested in the dynamics of CD4+
T cells (uninfected and infected) during chronic HIV infection, we
only allow for proliferation and death of CD4+ T cells in the
model. The rest of the cell populations remain of constant size
during the course of the infection.
For uninfected CD4+ T cells, we set the death rate based on the
proliferation rate estimated in [80]. As argued in [95] the death
rate measured in [80] is not that of all CD4+ cells but only of
labelled cells, which are not a representative sample of the whole.
However, the proliferation rate measured is the proliferation rate
of the whole CD4+ population. Hence, because at equilibrium the
proliferation equals the death rate and since we are mainly
interested in the chronic phase of the infection, we set the death
rate of uninfected CD4+ T cells to 0.025 d21 which equates to a
lifespan of 40 days.
For infected CD4+ T cells, we consider two phases: 1) an eclipse
phase (when a cell is infected but not yet producing virions) and 2)
a productively infected phase. During the eclipse phase, infected
cells can neither be recognised by CD8+ T cells nor infect
uninfected CD4+ T cells; they die with the same rate as uninfected
cells. The eclipse phase is estimated to last 1 day [96,97]. In the
productively infected phase, cells die at an exponential rate with a
mean of 1 d21 (i.e. they have a mean lifespan of 1 day) [98]. This
death rate includes death due to all factors (e.g. CD8+ T cell
killing, NK cell killing, and viral cytotopathicity).
We set the time to CD8+ T cell appearance to 10 days. We set
the proportion of productively infected cell death attributable to
CD8+ T cells to approximately 30% [28,48,49]. The total death
rate of productively infected CD4+ T cells is 1 d21, hence, we
assume an average death rate of 0.7 d21 before CD8+ T cell
activation and an average death rate of 0.95 d21 after activation,
allowing a small proportion of the death rate (<5%) to be
attributable to the single epitope-specific CD8+ T cell population
that is explicitly included in the model. This implies that the death
rate that is not attributed to the total CD8+ T cell population is the
same before and after the activation of the CD8+ T cells. To allow
for stochastic effects, the lifespan of infected cells, which is the
reciprocal of the death rate, is sampled for each infected cell from
Can Non-lytic CD8+ T Cells Drive HIV-1 Escape?
PLOS Pathogens | www.plospathogens.org 8 November 2013 | Volume 9 | Issue 11 | e1003656
a normal distribution (mean6sd) of 1.460.25 days before
introducing CD8+ T cell in the model and 1.0560.25 days after
day 10 (not including the death rate attributable to the explicitly
modelled specific-CD8+ T cell population).
Conjugate formation
We explicitly model the formation of conjugates between the
single epitope-specific CD8+ T cell population included in the
model and wild-type infected CD4+ T cells. Once a CD8+ T cell
encounters a target cell it must make the decision of ‘acting or
moving on’; we call the time this takes the scanning time. The time that
it takes a T cell to scan its target is estimated to be 7+2 min [41]
and this process is explicitly incorporated in the model. In general,
the decision to act is related to the characteristics of the TCR-
pMHC interaction and the level of pMHC expression on the
surface of the target cell [99]. This process is simulated in the model
via a probability which defines the decision of the CD8+T cell upon
encounter to which we refer as probability of recognition and is discussed
below. If the CD8+ T cell recognises the cell as infected then the
interaction time begins. The interaction time is set to between 10–
30 min, in agreement with measurements obtained with intravital
multiphoton microscopy [41,42]. For the lytic model we refer to this
interaction time as the ‘‘duration of killing’’, for the non-lytic models
we refer to this interaction time as the ‘‘duration of secretion’’. The
conjugates remain immobile during both scanning and interaction
time. This is a good approximation of the underlying biological
process; in [41,56] the conjugates of T cells with B cells and
granuloma cells respectively are immobile within minutes of
recognition. If the CD8+ T cell fails to recognise that the cell is
infected then it will disassociate and move on to another target.
Two additional aspects of the CD8+ T cell and target cell
encounter are incorporated in the model: 1) multiple CD8+ T
cells can kill the same target [100,101] and 2) multiple targets
can be killed by a single CD8+ T cell as observed in vitro [42].
The latter is further supported by the configuration of the
contact between TCR and APCs; during recognition of a target
cell the microtubule-organising center (MTOC) of the CD8+ T
cell polarises towards the immunological synapse. The high
motility of the MTOC allows for rapid switch of polarization
between targets [102]. However, as found in [101] most of the
CD8+ T cells in conjugate formation did not have more than
four target cells bound to them, an observation that we
implement in the model.
Target recognition by CD8+ T cells
The effectiveness of CD8+ T cells is dependent on their ability
to successfully survey potentially infected cells and recognise them
as targets. The recognition is dictated by a series of factors such as:
1) the level of antigenic stimulation [103,104], 2) the structural
rearrangements of TCR-binding [105], 3) the confinement time of
the TCR-pMHC interaction [106], 4) the formation of the
peptide-MHC complex [107] and others. We simulate the
stochasticity of this process by setting a probability of recognition
(Pr) of an infected target once the initial scanning time is
completed. If the target is successfully recognised then the CD8+ T
cell will act (either killing the target if it is operating lytically or
secreting soluble factors if it is operating non-lytically). The
probability of recognition is one of the parameters which allows us
to vary the immune control exerted by the specific CD8+ T cell
population included in our simulations.
Lytic and non-lytic viral suppression
The lytic response can be divided into at least three stages [108]:
1) CD8+ T cells survey potential target cells and recognise a
subgroup of them, 2) they then form a conjugate with their target
in order to deliver the lethal hit and 3) once the target lyses, they
continue hunting for new targets. All these stages are explicitly
included in the model. A CD8+ T cell might need to ‘rearm’
before moving on to their next target [109,110] or pause before
identifying a new target [41] therefore increasing the duration of
this process (we vary this parameter in order to investigate its
effect).
The non-lytic response can be summarised in the following
steps: 1) CD8+ T cells survey potential target cells and recognise a
subgroup of them, 2) they form a conjugate with their target and 3)
they secrete soluble factors which suppress viral production or
infection. We model the reduction of infectivity by not allowing
the infection of uninfected CD4+ T cells that ‘interact’ with the
soluble factors. In a similar way, we model the suppression of viral
production by not allowing infected cells to infect other cells once
the former ‘interact’ with the secreted factors. The duration of the
conjugate is set to 10–30 min as reported in [41]. We simulate the
following different secretion patterns: 1) localised effect, where
only the wild-type infected cell in conjugate with the CD8+ T cell
is affected, 2) a polarised (grid radius, r=1) effect where all the cells
one ‘side’ (in grid terms) of the CD8+ T cell are affected and 3) a
diffusive pattern where all the cells equidistantly found in the
immediate or broader area around the CD8+ T cell are affected
by the soluble factor. We considered a number of different radii of
diffusion: r = 1 (26 nearest cells affected), r = 2 (124 cells affected),
r = 3 (342 cells affected), r = 4 (728 cells affected), r = 5 (1330 cells
affected) and r = 6 (2196 cells affected). The duration of the effect
depends on the soluble factor under consideration. We focus on
RANTES as a case study. The recycling time for CCR5 receptors
after interaction with RANTES has a half-life of 6–9 hrs [67] so
we set the total duration of the RANTES ‘protective effect’ on
uninfected CD4+ T cells to 10 hrs; after that period the uninfected
cells can again be infected either with the wild-type or the variant
strain. The duration of the protection conferred by the soluble
factor is varied to ascertain its impact. In the results presented we
consider 100% protection of the uninfected targets unless
otherwise stated; reducing the protection to 50% reduced the
frequency but not the rate of escape.
For lytic killing, the target cells are lysed at the time that the
conjugate is detached. For non-lytic responses, the secretion of
soluble factors is stopped after conjugate resolution. This is
supported by experimental observations. In [111] it is shown that
IFN-c production from activated CD8+ T cells is terminated
immediately after the contact of the T cell and its cognate antigen
is disrupted. In the same study [111] , in vitro experiments indicate
that peptide-pulsed spleen cells cause the production of cytokines
(IFN-c and TNF-a) by LCMV-specific CD8+ T cells within
30 mins. In vivo, no cytokine production was observed in the
absence of stimulation.
Quantifying CD8+ T cell killing and viral escape
The escape variant. We initiate the simulations with 1–2
wild type-infected cells. Cells infected with the escape variant are
introduced at day 50 post infection at a frequency equal to 30% of
the wild-type infected cell population unless otherwise stated.
Reducing the initial variant frequency to 10% (corresponding to
approximately 10 infected cells) reduced the frequency but not the
rate of escape. Variant-infected cells cannot be recognised by the
single epitope-specific CD8+ T cells but are recognised by all other
CD8+ T cells.
Estimated viral escape rate. Following [49] the rate of viral
escape is estimated by fitting the following equation to the
simulated data.
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where p(t) is the proportion of variant-infected cells at time t; c is
the escape rate and g is the ratio of wild type to variant infected
cells when the variant is introduced.
Simulations
We run the simulation from the time of infection to verify that
the model predicts plausible viral expansion. However, we focus
on the analysis of the results obtained after the set-point has been
attained.
For all the calculations presented in this study, we run a
minimum of 10 up to a maximum of 100 simulations for each
situation with identical initial conditions and parameter values but
different initial seeding of the C++ pseudorandom algorithm.
Supporting Information
Text S1 Supplementary Text S1 contains the following: Figure
S1. Duration of CD8+ T cell killing has little impact on the
observed killing rates. Figure S2. The motility of the simulated
CD8+ T cells resembles a random walk. Figure S3. The mean
CD8+ T cell speed decreases as the probability of recognition of
infected targets increases. Figure S4. For CD8+ T cell operating
via a lytic mechanism, the proportion of infected cells at set point
decreases as the probability of recognition increases. Figure S5.
New infections prevented under a non-lytic CD8+ T cell response
that blocks infection. Figure S6. Number of infected CD4+ T cells
‘blocked’ from viral production under a non-lytic CD8+ T cell
response that blocks production. Figure S7. Set-point of
productively infected cells under a non-lytic CD8+ T cell response
that blocks production. Figure S8. New infections prevented under
a non-lytic CD8+ T cell response that blocks production. Figure
S9. Number of uninfected CD4+ T cells ‘protected’ from infection
with increasing effector population size. Figure S10. Immune
control exerted by a non-lytic response that reduces infectivity.
Figure S11. Immune control exerted by a non-lytic response that
reduces virion production. Equivalence of non-lytic models in
chronic infection. Supplementary methods.
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